|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis:Is the evidence of sufficient quality to develop recommendations?显示文摘BACKGROUND The standard management of autoimmune hepatitis(AIH)is based on corticosteroids,alone or in combination with azathioprine.Second-line treatments are needed for patients who have refractory disease.However,high-quality data on the alternative management of AIH are scarce.AIM To evaluate the efficacy and safety of tacrolimus and mycophenolate mofetil(MMF)and the quality of evidence by using the Grading of Recommendations Assessment,Development and Evaluation approach(GRADE).METHODS A systematic review and meta-analysis of the available data were performed.We calculated pooled event rates for three outcome measures:Biochemical remission,adverse events,and mortality,with their corresponding 95%confidence intervals(CI).RESULTS The pooled biochemical remission rate was 68.9%(95%CI:60.4-76.2)for tacrolimus,and 59.6%(95%CI:54.8-64.2)for MMF,and rates of adverse events were 25.5%(95%CI:12.4-45.3)for tacrolimus and 24.1%(95%CI:15.4-35.7)for MMF.The pooled mortality rate was estimated at 11.5%(95%CI:7.1-18.1)for tacrolimus and 9.01%(95%CI:6.2-12.8)for MMF.Pooled biochemical remission rates for tacrolimus and MMF in patients with intolerance to standard therapy were 56.6%(CI:43.4-56.6)vs 73.5%(CI:58.1-84.7),and among non-responders were 59.1%(CI:48.7-68.8)vs 40.8%(CI:32.3-50.0),respectively.Moreover,the overall quality assessments using GRADE proved to be very low for all our outcomes in both treatment groups.CONCLUSION Tacrolimus and MMF are in practice considered effective for patients with AIH who are non-responders or intolerant to first-line treatment,but we found no high-quality evidence to support this statement. | Mohammadreza Abdollahi Neda Khalilian Ekrami Morteza Ghojazadeh H Marike Boezen Mohammadhossein Somi Behrooz Z Alizadeh | 2020 | World Journal of Gastroenterology2020，26，38： | 5 |
| 2 | Endoscopic retrograde cholangiopancreatography outcome from a single referral center in Iran显示文摘BACKGROUND: Endoscopic retrograde cholangiopancreato- graphy (ERCP) is the first choice for diagnostic evaluation of the pancreatic and biliary tree and can be accompanied by a high diagnostic sensitivity and a poor therapeutic outcome. In the current study, we described our experiences in the indications, findings, and technical success of ERCP in a sample of the Iranian population admitted to a referral center in Iran. METHODS: In a retrospective review database-based study, 780 patients (393 males and 387 females; mean age 57.5 years) who had undergone diagnostic and therapeutic ERCP with the primary diagnosis of hepatobiliary disorder between 2006 and 2008 at Taleghani Hospital in Tehran were reviewed. The key data were demographic characteristics, clinical information, laboratory parameters, as well as post-ERCP complications. RESULTS: A history of cholecystectomy was found in about one-third (36.3%) of participants and 80 (10.3%) out of 780 patients had a previous history of biliary stone. A minority (1.4%) of the patients suffered from hepatobiliary carcinomas, and 11 patients had cirrhosis. The most common clinical manifestations in the patients undergoing diagnostic ERCP were icterus (47.3%), weight loss (31.2%), and dark urine (26.9%). Selective biliary cannulation was technically successful in 87.0% of the patients; however, cannulation failed in 13.0%. The most frequent final diagnosis of ERCP was common bile duct stone that was detected in 40.1% of the patients. The ERCP results in 11.0% of the patients were normal. Regarding appropriate treatment, successful stenting was performed in 43 patients (15.2%). Among post-ERCP complications, pancreatitis was the most adverse event withan incidence rate of 3.3%. Other complications including local bleeding, cholangitis and gastrointestinal perforation, rarely occurred. Post-ERCP pancreatitis was reported in 1.8% of men and 3.6% of women (P=0.120). Pancreatitis was more common in women below 70 years than in those who were older than 70 years (3.6% versus 0.5%; OR: 8.216, P=0.015). This might be due to the more functionally active pancreas in younger women than in the older ones. However, other complications were similar in the two age groups. CONCLUSIONS: Based on our experience, ERCP indications, final diagnosis and related complications are comparatively consistent with those reported in other countries. The most common post-ERCP complication is pancreatitis that is more often observed in younger patients. | Amir H Mohammad Alizadeh Esmaeil S Afzali Mirhadi Mousavi Yaghoub Moaddab Mohammad R Zali | 2010 | Hepatobiliary & Pancreatic Diseases International2010，9，4： | 3 |
| 3 | Exacerbation of Acanthamoeba keratitis in animals treated with anti-macrophage inflammatory protein 2 or antineutrophil antibodies显示文摘 | Hurt M Apte S Leher H Howard K Niederkorn J Alizadeh H | 2001 | Infect Immun2001，69，： | 1 |
| 4 | The role of macrophages in Acanthamoeba keratitis显示文摘 | van Klink F Taylor WM Alizadeh H Jager MJ van Rooijen N Niederkorn JY | 1996 | Invest Ophthalmol Vis Sci1996，37，： | 1 |
| 5 | Can intracoronary stem cell injection permanently improve cardiac function after myocardial infarction? 显示文摘 | Abbasi M Javan H Alizadeh B | 2011 | Interactive cardiovascular and thoracic surgery2011，12，2： | 1 |
| 6 | Systemic immune response to Acanthamoeba keratitis in the Chinese hamster显示文摘 | van Klink F Leher H Jager MJ Alizadeh H Taylor W Niederkorn JY | 1997 | Ocul Immunol Inflamm1997，5，： | 1 |
| 7 | Adaptive immune responses to Acanthamoeba cysts显示文摘 | McClellan K Howard K Mayhew E Niederkorn J Alizadeh H | 2002 | Exp Eye Res2002，75，： | 1 |
| 8 | Apoptosis as a mechanism of cytolysis of tumor cells by a pathogenic free-living amoeba显示文摘 | Alizadeh H Pidhemey MS Mcculley JP | 1994 | Infect Immun1994，62，4： | 1 |
| 9 | Investiga- tion of grain refinement in A1/A1203/B4C nano-composite produced by ARB 显示文摘 | Akbari Beni H Alizadeh M Ghaffari M | 2014 | Composites Part B: Engineering2014，58，： | 1 |
| 10 | Synthesis, structure, and characterization of a new sandwich type arsenotungstocerate, ^12-显示文摘 | Alizadeh M H Eshtiagh-Hosseini H Khoshnavazi R | 2004 | J Mole Struct2004，688，： | 1 |
| 11 | Seaso-nality patterns in tanker spot freight rate markets 显示文摘 | KAVUSSANOS M G ALIZADEH A H | 2002 | Economic Modelling2002，19，5： | 1 |
| 12 | In vitro shoot culture and microtuber induction in the steroid yam Dioscorea composita Hemsl显示文摘 | Sedigeh Alizadeh Sinclair H Mantell Ana MariaViana | 2000 | Plant Cell Tissue and Organ Culture2000，53，： | 1 |
| 13 | The role of contact lenses, trauma, and lungerhans cells in a Chinese Hamster model of acanthamoeba keratitis显示文摘 | Van Klink F Alizadeh H He Yu | 1993 | Invest Ophthalmol Vis Sci1993，34，6： | 1 |
| 14 | Isolation and molecular characterization of toxigenic Vibrio parahaemo- lyticus from the Kii Channel, Japan 显示文摘 | Zahid H M Afework K Alizadeh M | 2006 | Microbiol Re- search2006，161，： | 1 |
| 15 | A pig model of acanthamoeba keratitis: transmission via contaminated contact lenses显示文摘 | He Yu McCulley JP Alizadeh H | 1992 | Invest Ophthalmol Vis Sci1992，33，8： | 1 |
| 16 | Effects of ammonia fiber explosion treatment on activity of endoglucanase from Acidothermus cellulolyticus in transgenic plant 显示文摘 | Teymouri F Alizadeh H Laureano-Perez L Dale B Sticklen M | 2004 | Appl Biochem Biotechnol2004，116，： | 1 |
| 17 | Trading volume and volatility in the shipping forward freight market 显示文摘 | ALIZADEH A H | 2013 | Transportation Research Part E Logistics & Transportation Review2013，49，1： | 1 |
| 18 | A Markov regime switching approach for hedging energy commodities显示文摘 | ALIZADEH A H NOMIKOS N K POULIASIS P K | 2008 | J Banking&Fi-nance2008，32，9： | 1 |
| 19 | Synthesis of soluble and thermally stable polyimide from new diamine bearing N - formamide pendent group 显示文摘 | Ghaemy M Alizadeh R Behmadi H | 2009 | European Polymer Journal2009，45，11： | 1 |
| 20 | Role of mucosal IgA in the resistance to Acanthamoeba keratitis显示文摘 | Leher HF Alizadeh H Taylor WM Shea AS Silvany RS van Klink F | 1998 | Invest Ophthalmol Vis Sci1998，39，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员